Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
- 주제(키워드) Triple-negative breast cancer , Chemotherapy , Prognosis , P53 , Immunohistochemistry
- 주제(기타) Oncology
- 설명문(일반) [Bae, Soo Youn; Yang, Hsien Wen; Jung, Seung Pil] Korea Univ, Div Breast & Endocrine Surg, Dept Surg, Anam Hosp,Coll Med, 73 Inchon Ro, Seoul 02841, South Korea; [Nam, Seok Jin] Sungkyunkwan Univ, Dept Surg, Samsung Med Ctr, Sch Med, Seoul, South Korea; [Jung, Yongsik] Ajou Univ, Dept Surg, Sch Med, Suwon, Gyeonggi Do, South Korea; [Lee, Sae Byul] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea; [Park, Byung-Woo] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea; [Lim, Woosung] Ewha Womans Univ, Mokdong Hosp, Coll Med, Dept Surg, Seoul, South Korea; [Jung, Sung Hoo] Chonbuk Natl Univ, Sch Med, Chonbuk Natl Univ Hosp, Dept Surg, Jeonju, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 SPRINGER
- 발행년도 2018
- URI http://www.dcollection.net/handler/ewha/000000156416
- 본문언어 영어
- Published As http://dx.doi.org/10.1007/s10549-018-4928-2
초록/요약
PurposeTP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC.MethodsA total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 p53-positive (+) TNBC' patients and 5062 p53-negative (-) TNBC' patients.ResultsIn univariate analysis, p53(+) TNBC had a worse prognosis than p53(-) TNBC in patients not receiving chemotherapy (P=0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(-) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(-) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(-) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(-) TNBC, there was no risk reduction effect by chemotherapy.ConclusionThe prognosis of p53(+) TNBC has worse than p53(-) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(-) TNBC.
more